Loading clinical trials...

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances | Clinical Trials | Clareo Health

UNKNOWNPHASE1

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

NCT04934774•iCell Gene Therapeutics

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T cell lymphoma or leukemia

Detailed Description

Anti-CD7 CAR is a chimeric antigen receptor immunotherapy treatment designed to treat leukemia/lymphoma expressing CD7 antigen. T-cell acute lymphoblastic leukemia, T-acute lymphoblastic lymphoma and T-cell non-Hodgkin lymphoma are a subset of leukemias and lymphomas that are positive for the surface protein CD7. The purpose of this study is to evaluate the efficacy and safety of anti-CD7 CAR T cells.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed written informed consent; Patients volunteer to participate in the research
•2. Diagnosis is mainly based on the World Health Organization (WHO) 2008
•3. Patients have exhausted standard therapeutic options
•4. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
•5. Female must be not pregnant during the study

Exclusion Criteria

•1. Patients declining to consent for treatment
•2. Prior solid organ transplantation
•3. Potentially curative therapy including chemotherapy or hematopoietic cell transplant
•4. Any drug used for GVHD must be stopped \>1 week

Locations (1)

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

Key Dates

Start Date

December 1, 2020

Primary Completion Date

June 1, 2023

Completion Date

June 1, 2023

Last Updated

June 22, 2021

Enrollment

ESTIMATED participants

Conditions

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-cell Non-Hodgkin Lymphoma

Interventions

CD7 CAR T cells

BIOLOGICAL

Contacts

Kevin Pinz, MS

CONTACT

6315386218 kevin.pinz@icellgene.com

Yupo Ma, MD/PhD

CONTACT

7024658132 yupo.ma@icellgene.com

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

NCT05376111

T-cell Acute Lymphoblastic LeukemiaRecruiting

View study

RECRUITINGPHASE1

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

NCT05679895

T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Inclusion Criteria

Exclusion Criteria

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas